Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRA737 with Gemcitabine +/- Cisplatin in Advanced Cancer
NCT02797977Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of SRA-737 in solid tumor (advanced stage), High-Grade Serous Ovarian Carcinoma (HGSOC), small cell lung cancer (SCLC), soft tissue sarcoma (STS), Cervical Cancer (CC), sponsored by GSK. Started Jul 2016; status: completed.
02
Drugs
SRA-737
03
Conditions
solid tumor (advanced stage)High-Grade Serous Ovarian Carcinoma (HGSOC)small cell lung cancer (SCLC)soft tissue sarcoma (STS)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02797977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797977.